Key Aspects of Therapeutic Portfolio

Genetic Immunity's topical dendritic cell targeting disease modifying therapeutic vaccine approach is:

• Versatile:
  • Clinically validated with DermaVir
  • Animal Proof of Concept for prototype vaccine candidates:
    • Intracellular bacteria (prototype: ChlamyDerm (Chlamydia))
    • Allergy (protoype: DermAll (dust mite))
  • Discovery programs in:
    • Human Papillomavirus (HupaDerm)
    • Prostate Cancer (ProstaDerm)
• Validated throughout the R&D pipeline
  • Mechanism of action, safety and efficacy demonstrated for three distinct vaccine candidates in routine animal models (mouse, rabbits and nonhuman primates).
  • Preclinical observations for DermaVir reflects the clinical observation in man.
  • Genetic Immunity's topical dendritic cell targeting approach has been demonstrated to be equivalent to the ex vivo approach in non-human primate studies.
  • These observations demonstrate that the Genetic Immunity approach can be pursued in multiple indications using standard, accepted animal models
• Simpler and more cost effective compared to the cumbersome and expensive ex vivo dendritic immunization approach.
• Enabled for rapid and cost effective new product development
  • New plasmid DNA encoding disease-specific antigens
  • Same Nanomedicine formulation and DermaPrep device
  • Same manufacturing technology
  • Similar biomarkers and toxicity profile